A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China
Conditions
Interventions
- BIOLOGICAL: SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose
- BIOLOGICAL: SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine High dose
- DRUG: Placebo
Sponsor
AIM Vaccine Co., Ltd.
Collaborators
- [object Object]
- [object Object]